Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
The conference call will be webcast live from the company鈥檚 website and will be available via the following link: . A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company鈥檚 website at .
The conference call dial-ins can be accessed by registering via this .
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit or follow us on or .
View source version on businesswire.com:
Investors
Shayla Gorman
[email protected]
(619) 393-1545
Media
Tracy Morris
[email protected]
(650) 380-4413
Source: Veracyte, Inc.
